AI drug developer Alto Neuroscience raises $25M and more digital health fundings
Mobi Health News
JANUARY 31, 2023
Cough monitoring company C-mo Medical Solutions and sexual healthcare provider TBD Health also announced funding rounds.
Heal plans layoffs ahead of potential sale and more digital health briefs
Mobi Health News
DECEMBER 28, 2022
Drug development platform Quris raised another $9 million, and PharmStars is accepting applications for its accelerator cohort focused on women's health and health equity.
Drug Development 
342
342 Join 48,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Truveta welcomes new health system members and raises $95M; YuLife scores $70M to transform life insurance and more digital health fundings
Mobi Health News
JULY 15, 2021
Also: Entos works to improve drug development after closing its Series A round and Castor plans to build out its decentralized clinical trial platform with a $45 million investment.
Drug Development 246
246 
A roadmap by the FDA for incorporating digital health technologies in clinical trials
Digital Health Global
MARCH 30, 2023
The FDA has announced several guidelines and plans to hold at least one public meeting on digital health technologies (DHTs) to be used in drug clinical trials by the end of the year. Drug development process questions the reliability and accuracy of DHT products.
Digital Health 167
167 
Daewoong Pharmaceutical revolutionizes drug development with AI-Driven DAISY system
Digital Health Global
MARCH 28, 2024
Daewoong Pharmaceutical , a prominent player in the South Korean pharmaceutical industry, has unveiled its groundbreaking drug development system, Daewoong AI System (DAISY). About DAISY DAISY represents the culmination of over 40 years of research and development by Daewoong Pharmaceutical.
Digital Health Technologies in Clinical Trials
Digital Health Global
NOVEMBER 30, 2023
Digital Health Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones
Digital Health Global
JANUARY 10, 2024
As we look forward to an exhilarating 2024, we believe this partnership will pave the way for significant advancements in the field of drug R&D for the benefit of the patients,” explained Khai Pham, CEO of ThinkingNodeLife.ai Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development
Digital Health Global
JANUARY 26, 2024
NEW YORK–(BUSINESS WIRE)– Deliberate AI , a digital health technology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
Biofourmis announces major agreements with top pharmaceutical companies
Digital Health Global
FEBRUARY 19, 2024
Biofourmis , a global digital health and clinical trial solutions leader, announces four key partnerships with top pharmaceutical firms. Beyond digital biomarker and endpoint expertise, pharmaceutical partners are leveraging Biofourmis to streamline study timelines through its Digital Clinical Trials solution.
Pharmaceuticals 166
166 
Health Consumers Are Now Amazon-Primed for Healthcare – HealthConsuming Explains, Part 2
Health Populi
APRIL 29, 2019
In the past couple of months, Amazon announced many health-related plans and developments, including: Accepting medical and health savings accounts (HSAs) to pay for consumer health products like over-the-counter drugs. See more on that recommendation, and subsequent social media frenzy, here on Health Populi ).
HIPAA 307
307 
How Digital Health improves patient experiences in Alzheimer’s care
Digital Health Global
DECEMBER 5, 2023
Despite a history of drug development failures in the field, recent work provides reason for optimism, showing a possible therapeutic arsenal to limit disease progression at an early stage.
Blockchain in Healthcare: A Vehicle Towards Digital Health 2.0?
The Digital Health Corner
MARCH 26, 2018
In this scenario, a patient can digitally determine who should have access to the medical record (and which portion), which person(s) or entities saw or modified the record (and what portion) and when. Herding a patient’s data from many sources into a single record has always been a lofty goal of digital health.
Digital Health 117
117 
The next revolution in the pharmaceutical industry: the transformative potential of AI
Digital Health Global
SEPTEMBER 19, 2023
Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care. The clinical trials phase represents a crucial turning point in drug development, but is often characterised by inefficiencies and delays.
Pharmaceuticals 167
167 
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson’s Disease
Digital Health Global
MARCH 26, 2024
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson’s disease.
Koneksa Announces New Multi-Domain Model for Functional Status Assessment Enabled by Digital Health Technologies
Digital Health Global
JANUARY 4, 2024
Koneksa’s innovative digital model aims to address limitations in existing functional status assessments by leveraging digital health technologies (DHTs) for both objective and self-reported outcomes. Chief Medical Officer, Koneksa. Chief Scientific Officer, Koneksa.
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Drug Development 128
128 
COVID-19 has accelerated adoption of non-contact patient monitoring technology, says Frost & Sullivan analysis
Healthcare IT News - Telehealth
MAY 29, 2020
“These technologies can also be leveraged by pharmaceutical companies to monitor the results of the drugs developed by them," said Ashish Kaul, technical insights senior research analyst at Frost & Sullivan. THE LARGER CONTEXT. She cites examples such as Binah.ai
Mental health 179
179 
Digital Healthcare Transformation: Improving Patient Experience and Outcomes
Digital Health Global
MAY 10, 2023
Enhancing outcomes for patients with the implementation of digital technologies, such as artificial intelligence (AI) and big data analysis, empowers healthcare professionals to make better-informed decisions. Artificial Intelligence is utilized in various areas of healthcare, ranging from drug development to medical image analysis.
A New Resource to Help Advance Patient-Focused Drug Development with DHTs
ActiGraph
JUNE 21, 2024
This patient-centric approach ensures that new treatments are not only effective but that they improve quality of life, enhance adherence to therapy, and ultimately achieve better health outcomes.
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
Digital Health Global
NOVEMBER 20, 2023
–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. in 2060.
Life Science 88
88 
MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment
Digital Health Global
JANUARY 9, 2024
The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process. “
Digital Health v HealthTech: What is the difference?
Lloyd Price
JULY 15, 2024
Exec Summary: Digital Health is a subset of Healthtech. Digital Health focuses on the individual patient, while Healthtech focuses on the entire healthcare ecosystem. Artificial intelligence: This is a rapidly developing field that has the potential to revolutionize healthcare. Subscribe Today!
Drug Discovery and Early Development Outsourcing Services Industry Analysis – M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion – ResearchAndMarkets.com
Digital Health Global
APRIL 5, 2024
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.
Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials
Digital Health Global
MARCH 2, 2023
Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
Life Science 88
88 
Genialis and Debiopharm Set Up Biomarker Discovery Collaboration
Digital Health Global
JANUARY 25, 2024
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
Koneksa Announces Partnership with Beacon Biosignals for Clinical Trial in Sleep and Neurologic Disorders Using EEG Biomarkers
Digital Health Global
JUNE 13, 2023
“The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer
Digital Health Global
APRIL 25, 2024
This pilot study represents a critical step in leveraging digital health technology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
Health Data 88
88 
Vital Lines September 2023
Redox
SEPTEMBER 26, 2023
Top stories CMS creates all-payer model for states CMS is offering an all-payer funding opportunity of up to $12M for eight states to improve population health. Two trends might be changing the game for private clouds: 1) flat/increased pricing for the public cloud and 2) dropping data center costs.
FHIR 105
105 
Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption
Digital Health Global
JANUARY 28, 2025
Recently, the company launched Medable AI and Medable Studio to automatically convert outcomes assessments into fully digital eCOAs in seconds now accessible on Google Cloud Marketplace. Medable will also be presenting with Christina Fawcet , Director of Digital Health Delivery at GSK, on Wednesday, Feb. 5 at 9:55am.
Life Science 88
88 
QuantHealth Announces $15M Series A for its AI Platform That Enhances Success of Clinical Trials
Digital Health Global
AUGUST 30, 2023
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drug development. This decline is happening at a time when the need for efficient drug development has never been greater. This happens because there are major gaps in the research needed to support clinical trials.
BioTech 88
88 
Debiopharm Innovation Fund Launches New Seed Funding Activity to Accelerate Digital Transformation of Cancer Care and Pharma R&D
Digital Health Global
SEPTEMBER 28, 2023
The new seed funding activity will therefore pave the way for the next generation of treatments and digital health, providing healthcare professionals with better tools to improve experiences and outcomes for patients. Since 2017 Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds.
How to Leverage DTx with Your Digital Health Strategy | Part 1 of 2
Xealth
JUNE 27, 2023
David Slifka, Vice President, Commercial Enablement The digital health ecosystem is a complex place. Confusion abounds among healthcare providers regarding digital therapeutics (DTx) terminology and classifications, and understandably so. DTx fall within the digital medicine subset within the larger digital health ecosystem.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
Healthcare IT Today
NOVEMBER 1, 2022
Deerfield invests across the life science, medical device, diagnostic, digital health, and health service industries at every stage of evolution. The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology.
Life Science 105
105 
New Data Reveals Decentralized Clinical Trials Linked to Improved Diverse Participation Across Many Underrepresented Demographics
Digital Health Global
JANUARY 28, 2025
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium links decentralized clinical trial (DCT) approaches to notably higher participation rates across multiple demographic groups. PALO ALTO, Calif.–(BUSINESS
Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders
Digital Health Global
JUNE 20, 2023
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.
Life Science 88
88 
Let’s Save the Date and Make Patient Engagement Official in 2022
Society for Participatory Medicine
JANUARY 27, 2022
Clinical trials, care encounters, and access to data were found guilty of not meeting patients where they are and not adequately addressing the social determinant of health factors, creating barriers for patients. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years.
BioTech 97
97 
CORRECTING and REPLACING New Data Reveals DCT Components Linked to Improvements in Clinical Trial Access Among Underrepresented Communities
Digital Health Global
JANUARY 29, 2025
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium linking decentralized clinical trial (DCT) approaches to notably higher proportional representation among select demographic subgroups. Medable Inc., 5 at 9:55am.
Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%
Digital Health Global
JANUARY 8, 2024
A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively. Medable, which ranked in the top 8% of software companies on the 2023 Inc.
Life Science 88
88 
Medable and Masimo Partner to Bring Best-in-Class Wearable Devices to Clinical Research, Capturing Rich Subjective and Objective Data
Digital Health Global
MAY 29, 2024
A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe
Digital Health Global
JUNE 2, 2024
About Massive Bio: Massive Bio’s vision is to cover entire Pharma value chain with disruptive solutions to improve entire ecosystem from drug development to commercialization.
#091: Francesca Wuttke on Digital Transformation, Startups and Corporate Relationships
Digital Health Today
SEPTEMBER 6, 2019
In her role, she is responsible for finding use cases to apply digital solutions and services across the business and bring efficiencies that save time, lower costs and open up new business channels for Almirall. How to define and win buy-in of ‘Digital Transformation' within pharma companies. Digital Health Events.
Bonus Features – August 7, 2022 – Patients like digital health but have security concerns, healthcare leaders optimistic “seamless” care is coming, and more
Healthcare IT Today
AUGUST 7, 2022
Data platform H1 is teaming with Lokavant , a clinical trial analytics vendor, to help clinical trial teams determine the best sites for trials in an effort to accelerate drug development.
eCare 75
75 
The rise of mHealth and the convergence of medicine with AI and Big Data
Lloyd Price
FEBRUARY 20, 2020
At Mangrove, we believe digital health represents one of the very largest opportunities for value creation. It will also explain the value of clinically- proven software interventions, while dispelling the myth that doctors are better placed to build digital health businesses.
mHealth 78
78 
#099: Dr. David Fajgenbaum on Chasing a Cure for Rare Disease
Digital Health Today
FEBRUARY 24, 2020
On Digital Health Today, I leverage my experiences to help great leaders and innovators tell their stories and connect to users, investors and other stakeholders. Digital Health Today would not be possible without our valuable partners. Now available on Health Podcast Network! Meet our Premier Partners.
Digital Health 104
104 
Let's personalize your content